Top 5 FDA-Cleared Apps for Primary Care

News
Slideshow

From a mobile EKG monitor to a digital urinalysis app, these medical "devices" are changing the way healthcare is delivered.

Recent Videos
New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time
Related Content
Machine Learning Tool Detects Severe Subjective Cognitive Decline in Menopausal Women / image courtesy of Shandong University

Machine Learning Predicts Subjective Cognitive Decline During Menopause: Novel Framework for Early Detection

Grace Halsey
July 11th 2025
Article

Key predictors of the severity of self-reported cognitive complaints among nurses going through menopause included symptom severity and climacteric stage.

The Weekly Dose: Clinical Updates on Cancer Detection, Cognitive Screening, CVD Prevention, Atopic Dermatitis Treatment

The Weekly Dose: Clinical Updates on Cancer Detection, Cognitive Screening, CVD Prevention, Atopic Dermatitis Treatment

Sydney Jennings
July 8th 2025
Podcast

Discover essential clinical insights on Alzheimer disease screening in primary care, eczema treatments, and the latest in cancer detection and diet impacts on CHD risk.

GLP-1 Therapy for Obesity Requires Substantial Nutritional Framework, Multidisciplinary Support, Joint Advisory Warns

GLP-1 Therapy for Obesity Requires Substantial Nutritional Framework, Multidisciplinary Support, Joint Advisory Warns

Grace Halsey
July 9th 2025
Article

GLP-1 medications are transforming obesity medicine but strong evidence points to a need for integrating nutrition and lifestyle support for lasting weight loss and health benefits.

The Weekly Dose: How Medicaid Policies Impact Postpartum Depression Care

The Weekly Dose: How Medicaid Policies Impact Postpartum Depression Care

Sydney Jennings;Elizabeth Mollard, PhD
May 22nd 2025
Podcast

At ACOG 2025, Elizabeth Mollard, PhD, discussed her research on Medicaid PPD screening and coverage policies on PPD diagnosis.

First Patient Receives Lipocene's LPCN 1154 for Postpartum Depression in Phase 3 Clinical Trial / image credit ©grooveridez/stock.adobe.com

First Patient Receives Lipocene's LPCN 1154 for Postpartum Depression in Phase 3 Clinical Trial

Grace Halsey
June 27th 2025
Article

Lipocene anticipates the phase 3 trial data will support an NDA submission for LPCN 1154 to treat PPD in mid-2026, the company said.

Once-Monthly Maridebart Cafraglutide Produces Up to 20% Weight Loss in Phase 2 Trial

Once-Monthly Maridebart Cafraglutide Produces Up to 20% Weight Loss in Phase 2 Trial

Sydney Jennings
June 26th 2025
Article

ADA 2025: Once-monthly dosing led to significant weight loss in adults with obesity, with or without type 2 diabetes, reported researchers.

© 2025 MJH Life Sciences

All rights reserved.